Pharmaceutical company KalVista Pharmaceuticals Inc (NASDAQ:KALV) stated on Tuesday its net loss of USD5.9m (USD0.33) per basic and diluted share for the fiscal second quarter ended 31 October 2019.
This marks a decline in earnings when compared to a net loss of USD3.3m (USD0.22 per basic and diluted share) for the same period in 2018.
Revenue of USD3.9m were generated for the three months ended 31 October 2019, down over revenues of USD5.6m for the same period in 2018. Revenue in the three months ended 31 October 2019 consisted of the recognition of a portion of the upfront payment from Merck.
Research and development expenses of USD9.8m were recorded for the three months ended 31 October 2019, an increase versus USD7.9m for the same period in 2018, which reflects the ongoing clinical trial for KVD900 and an increase in expense related to preclinical activities.
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return